Canceriq Raises $14M Series B Funding To Improve Access To Innovations In Cancer Early Detection And Prevention

Mar 03, 2022•over 3 years ago

Amount Raised

$14 Million

Round Type

series b

Chicago

Description

CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14 million Series B financing round co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures. McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQ’s Series A lead investor, HealthX Ventures, also participated in the Series B round.

Company Information

Company

Cancer Iq

Location

Chicago, Illinois, United States

About

CancerIQ is the only cancer-focused precision health platform that empowers healthcare providers to detect cancer earlier and prevent it altogether across all patient populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations. Learn more at canceriq.com, follow CancerIQ on Twitter, LinkedIn or Facebook, and check out our latest eBook.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Canceriq Raises $14M Series B Funding To Improve Access To Innovations In Cancer Early Detection And Prevention

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information